TGFB1 and hepatocellular carcinoma: Galunisertib and sorafenib combination increased growth inhibition and apoptosis in HCC cell lines and ex-vivo tumor samples, emphasizing a crucial role for TGF-β1 inhibition in overcoming sorafenib resistance [201] and enhanced sorafenib-induced apoptosis [200].